Indeed, a randomized clinical trial showed that CBD reduced circulating resistin, a hormone associated with insulin resistance, and increased glucose-dependent insulinotropic peptide (GIP), which plays a role in preserving pancreatic β-cell function in T2D patients (Jadoon et al. 2016). Here, GIP is linked to type 2 diabetes mellitus.